2024
Bile acid-gut microbiota imbalance in cholestasis and its long-term effect in mice
Yang X, Xu Y, Li J, Ran X, Gu Z, Song L, Zhang L, Wen L, Ji G, Wang R. Bile acid-gut microbiota imbalance in cholestasis and its long-term effect in mice. MSystems 2024, 9: e00127-24. PMID: 38934542, PMCID: PMC11265269, DOI: 10.1128/msystems.00127-24.Peer-Reviewed Original ResearchGut microbiotaGut microbiota dysbiosisDysregulated gut microbiotaGut microbiota transplantationGerm-free miceVirulence factorsSmall intestinal bacteriaBile acid homeostasisMicrobiota dysbiosisDecreased diversityMicrobiota imbalanceMicrobiotaMouse model of cholestasisBile acidsMouse modelIntestinal bacteriaAcid homeostasisMicrobiota transplantationClinical management of patientsGutHepatic bile acidsLong-term effectsPre-clinical findingsModel of cholestasisManagement of patientsGut microbiota from B-cell-specific TLR9-deficient NOD mice promote IL-10+ Breg cells and protect against T1D
Yang X, Huang J, Peng J, Wang P, Wong F, Wang R, Wang D, Wen L. Gut microbiota from B-cell-specific TLR9-deficient NOD mice promote IL-10+ Breg cells and protect against T1D. Frontiers In Immunology 2024, 15: 1413177. PMID: 38903498, PMCID: PMC11187306, DOI: 10.3389/fimmu.2024.1413177.Peer-Reviewed Original ResearchGut microbiotaGerm-free miceToll-like receptor 9Increased gut permeabilityIntestinal microbiotaGut permeabilityT1D developmentGut microbiota compositionFecal samplesTransferred to germ-free miceGut barrier integrityBreg cell differentiationMicrobiota influenceMucin degradationMicrobiota compositionBreg cellsAltered microbiotaMicrobiota impactMicrobiotaGene expressionImmune regulationDevelopment of T1DCell differentiationGutNOD miceTlr9 deficiency in B cells leads to obesity by promoting inflammation and gut dysbiosis
Wang P, Yang X, Zhang L, Sha S, Huang J, Peng J, Gu J, Pearson J, Hu Y, Zhao H, Wong F, Wang Q, Wen L. Tlr9 deficiency in B cells leads to obesity by promoting inflammation and gut dysbiosis. Nature Communications 2024, 15: 4232. PMID: 38762479, PMCID: PMC11102548, DOI: 10.1038/s41467-024-48611-8.Peer-Reviewed Original ResearchConceptsToll-like receptor 9Gut microbiotaGut microbial communityTransferred to germ-free miceB cellsGerm-free miceTLR9 deficiencyKO miceGene sequencesGerminal center B cellsMicrobial communitiesMarginal zone B cellsGut dysbiosisFollicular helper cellsSelf-DNAMetabolic homeostasisAssociated with increased frequencyPro-inflammatory stateFat tissue inflammationGutHigh-fat dietMicrobiotaHelper cellsT cellsControl miceGut microbiota and therapy for obesity and type 2 diabetes
Zhang L, Wang P, Huang J, Xing Y, Wong F, Suo J, Wen L. Gut microbiota and therapy for obesity and type 2 diabetes. Frontiers In Endocrinology 2024, 15: 1333778. PMID: 38596222, PMCID: PMC11002083, DOI: 10.3389/fendo.2024.1333778.Peer-Reviewed Original ResearchGut microbiota compositionGut microbiotaMicrobiota compositionType 2 diabetesFunction of gut microbiotaHomeostasis of gut microbiotaMicrobiota-based approachesModulating gut microbiotaBariatric surgeryEffective anti-obesity treatmentQuality of life of individualsMicrobiotaMildly obese patientsSustained weight lossAssociated with obesityDiminished quality of lifeAnti-obesity treatmentObesity management strategiesGutQuality of lifeNon-surgical interventionsIncreased medical costsPublic health crisisMusculoskeletal disordersObese patients
2023
Distinct signatures of gut microbiota and metabolites in different types of diabetes: a population-based cross-sectional study
Hu J, Ding J, Li X, Li J, Zheng T, Xie L, Li C, Tang Y, Guo K, Huang J, Liu S, Yan J, Peng W, Hou C, Wen L, Xu A, Zhou Z, Xiao Y. Distinct signatures of gut microbiota and metabolites in different types of diabetes: a population-based cross-sectional study. EClinicalMedicine 2023, 62: 102132. PMID: 37593224, PMCID: PMC10430172, DOI: 10.1016/j.eclinm.2023.102132.Peer-Reviewed Original ResearchAdult-onset T1DHealthy controlsGut microbiotaT1D patientsShort-chain fatty acid-producing bacteriaPopulation-based cross-sectional studyGut microbial alterationsRecent epidemiological dataType 1 diabetesCross-sectional studyT2D patientsIntestinal disturbancesDifferential diagnosisSerum metabolitesEpidemiological dataPatientsStudy subjectsT1DDiabetesSignificant differencesAcid-producing bacteriaMicrobiotaMicrobial profilesNational Key ResearchMicrobial alterations
2021
Inflammasomes and Type 1 Diabetes
Pearson JA, Wong FS, Wen L. Inflammasomes and Type 1 Diabetes. Frontiers In Immunology 2021, 12: 686956. PMID: 34177937, PMCID: PMC8219953, DOI: 10.3389/fimmu.2021.686956.Peer-Reviewed Original ResearchConceptsType 1 diabetesMultiprotein complexesEnhanced toleranceMicrobial ligandsIslet autoantibody developmentImmune responseGenetic associationMicrobial stimulationAvailable inhibitorsImportant modulatorType 1 diabetes susceptibilityPathwayDiabetes susceptibilityAutoimmune processMicrobiota compositionAutoantibody developmentMicrobiotaAnimal modelsInflammasomeActivationGenetic riskType 1DiabetesHumansRole
2020
Crosstalk between circadian rhythms and the microbiota
Pearson JA, Wong FS, Wen L. Crosstalk between circadian rhythms and the microbiota. Immunology 2020, 161: 278-290. PMID: 33090484, PMCID: PMC7692254, DOI: 10.1111/imm.13278.Peer-Reviewed Original ResearchConceptsHost circadian rhythmsMicrobial oscillationsGene/protein expressionAspects of biologyCircadian rhythmMicrobial associationsMolecular oscillationsCircadian oscillationsMicrobial compositionMicrobial influenceCause diseaseMolecular techniquesHost metabolismDisease susceptibilityMicrobial changesProtein expressionPeripheral rhythmsMain inducerMicrobiotaSleep-wake cycleHost immunityCrosstalkClinical successPotential connectionMicrobesGut microbial metabolites alter IgA immunity in type 1 diabetes
Huang J, Pearson JA, Peng J, Hu Y, Sha S, Xing Y, Huang G, Li X, Hu F, Xie Z, Xiao Y, Luo S, Chao C, Wong F, Zhou Z, Wen L. Gut microbial metabolites alter IgA immunity in type 1 diabetes. JCI Insight 2020, 5 PMID: 32298241, PMCID: PMC7259536, DOI: 10.1172/jci.insight.135718.Peer-Reviewed Original ResearchConceptsType 1 diabetesGut microbiotaNOD miceImmune responseGerm-free NOD miceIgA immune responseIgA-mediated immunityHealthy control subjectsPotential therapeutic agentShort-chain fatty acid productionIgA immunityT1D preventionIgA responsesControl subjectsDecreased severityT1DTherapeutic agentsFunctional effectsMicrobiotaDiabetesPatientsUnderlying mechanismMiceImmunitySCFA
2015
The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity
Tai N, Wong FS, Wen L. The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity. Reviews In Endocrine And Metabolic Disorders 2015, 16: 55-65. PMID: 25619480, PMCID: PMC4348024, DOI: 10.1007/s11154-015-9309-0.Peer-Reviewed Original ResearchConceptsGut microbiotaAutoimmune type 1 diabetesType 2 diabetes mellitusInsulin-resistant type 2 diabetesMajor public health concernAltered gut microbiotaDevelopment of T1DType 2 diabetesType 1 diabetesGut microbiota compositionPublic health concernDiabetes mellitusPersistent hyperglycemiaMetabolic disordersRodent modelsMicrobiota compositionType 1ObesityDiabetesHealth concernPotential mechanismsMicrobiotaT2DT1DDisease development